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Background: Mesothelioma (MPM) is a rare malignant disease with a worse outcome. Fibroblast growth factor 1
(FGFR1) may be an interesting target for selective tyrosine kinases inhibitors (TKI) in MPM. The aim of this study was
to evaluate the amplification of the FGFR1 gene in patients suffering from MPM.
Findings: We identified nineteen male patients treated in our department between August 2008 and July 2010
matching the inclusion criteria. Mean age was 68 years. Histopathological examination confirmed thirteen patients
with epitheloid subtype, five with biphasic and one patient with sarcomatoid. Fluorescence in situ hybridization
analysis revealed no polysomy nor an amplification of the FGFR gene copy number in any case.
Conclusion: Regarding that also EGFR amplifications in MPM are absolute rarities, our findings may be a hint that
TKI’s will not satisfy the hope for a new era in the treatment of MPM.
Keywords: Personal medicine, Pleural, Asbestos, Pleuropneumonectomy, Decortication, ChemotherapyThe malignant pleural mesothelioma (MPM) is an asbes-
tos related highly aggressive malignancy arising from the
pleural surface [1]. Despite all advances in diagnostic pro-
cedures and therapeutic options, which were made over
the last decades, prognosis of MPM is still poor [2]. Most
therapeutic strategies like common systemic chemo-
therapy can improve the overall survival for only a few
months. However, alterations in receptor tyrosine ki-
nases (RTK’s) like over expression, mutation or amplifi-
cation of has been identified as targets for patient-
tailored therapy in a broad spectrum of malignancies. In
particular, “driver mutations”, like epidermal growth
factor receptor (EGFR), anaplastic lymphoma kinase
(ALK) and others, are major players involved in the
process of carcinogenesis. Physiologically regulating
proliferation, apoptosis and cell motility, gene amplifi-
cation and subsequent over expression of these genes
lead to relevant activation of pro-oncogenic pathways* Correspondence: Till.Ploenes@uni-wh.de
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unless otherwise stated.and correlates with response to tyrosine kinases inhibi-
tors (TKI’s). It has recently been suggested that the
fibroblast growth factor 1 (FGFR1) may be an interest-
ing target for selective TKI’s in MPM [3]. Amplification
of FGFR1 is already identified as a therapeutic target in
lung cancer, but up to now the role of FGFR1 in meso-
thelioma is unclear [4].
The aim of this study was to evaluate the amplification
of the FGFR1 gene in patients suffering from MPM.
In this retrospective study we investigated nineteen
patients suffering from histologically proofed MPM.
Histology was confirmed by thoracoscopy and classi-
fied according to the World Health Organization
(WHO) criteria. All patients were treated in our
department between 2008 and 2010. Patients were
selected based on the following criteria: no chemother-
apy prior tissue sampling, no other malignancy in the
medical history and sufficient tissue sampling from the
primary tumour. Clinical information was obtained by
medical records and our medical data base. The study
was approved by the local ethics committee (ethics com-
mittee of University of Witten/Herdecke, Nr. 126/2013).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients characteristics
Value n=19
Age (years) (mean, standard derivation) 68±9
Gender Male n=19
Asbestos exposure* n=11
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gated by FISH assay (Cytovision, Berlin, Germany) ac-
cording to the manufactures instructions. FISH signals
were analysed by microscopy performed by experi-
enced molecular biologists blinded to the clinical
parameters of each patient. FISH signals were classified
in analogy to the HER-2/neu scoring recommendations
and counted as amplification if a ratio of >2.2 was
observed, whereas a ration <1.8 was counted a negative
or not amplified. Due to the descriptive character of
this study no further statistic methodology was used.
We identified nineteen male patients treated in our
department between August 2008 and July 2010
matching the inclusion criteria. Mean age was 68 years.
Histopathological examination confirmed thirteen
patients with epitheloid subtype, five with biphasic and
one patient with sarcomatoid. Ten patients disclosed
exposure to asbestos, which was not confirmed histo-
logically in any case (Table 1). Fluorescence in situ
hybridization analysis revealed no polysomy nor an
amplification of the FGFR gene copy number in any
case (Figure 1).Figure 1 The figure shows a representative mesothelioma section (5
Zytovision, Germany (left panel). No amplification of FGFR (green signal
FGFR gene is shown. The white arrows indicate cells in which the green sig
(right panel).Findings
The MPM is a highly aggressive malignancy, withstand-
ing all current oncological treatment. The inhibition of
RTK’s may be a new treatment option in many malig-
nancies and may be an opportunity in the frustrating
treatment of MPM. The epidermal growth factor recep-
tor (EGFR) for example is over expressed in many
epithelial malignancies, against which TKI’s has been
developed. Although EGFR mutations are very rare, the
expression status of EGFR in MPM has been noted in
several publications [5]. The role of EGFR in MPM is
until now unclear, but the fact that MPM is a mesenchy-
mal and not an epithelial tumor may be a reason why
the role of EGFR in MPM will remain limited. Therefore
other RTK’s has to be evaluated for treatment of MPM.
Recently, FGFR1 has been identified as a potential thera-
peutic target for MPM in an experimental setting [3].
We examined in a pilot study nineteen tissue samples
of patients suffering from MPM for amplification of
FGFR1-gene. We could not discover any polysomy for
FGFR gene in the investigated tissue samples, neither
high nor low polysomy. Regarding that also EGFR ampli-
fications in MPM are absolute rarities, this may be a hint
that TKI’s will not satisfy the hope for a new era in the
treatment of MPM [6,7]. Further investigations concern-
ing the role of RTK’s and TKI’s in MPM are urgently
needed.
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